Shohreh Honarbakhsh

Shohreh Honarbakhsh

Auto-generated profile, based on publicly available information

Shohreh Honarbakhsh

St Bartholomew's Hospital, Barts Heart Centre, London; Queen Mary University of London

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
GDGurpreet Dhillon
Gurpreet Dhillon
SASyed Ahsan
Syed Ahsan
SHShohreh Honarbakhsh
Shohreh Honarbakhsh
WLWei Lim
Wei Lim
MBMarco Baca
Marco Baca
RHRoss J Hunter
Ross J Hunter

6 April 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
GDGurpreet Singh Dhillon
Gurpreet Singh Dhillon
SHShohreh Honarbakhsh
Shohreh Honarbakhsh
AMAntonio Di Monaco
Antonio Di Monaco
ACAnn Elizabeth Coling
Ann Elizabeth Coling
KLKernerová Lenka
Kernerová Lenka
RSRichard J. Schilling
Richard J. Schilling

6 July 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SHShohreh Honarbakhsh
Shohreh Honarbakhsh
Graham TaylorGraham Taylor
Graham Taylor
Human T-lymphotropic virus type 1 (HTLV-1), a retrovirus, is the causative agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukaemia/lymphoma (ATLL). The reported association with pulmonary disease such as bronchiectasis is less certain. A retrospective case review of a HTLV-1 seropositive cohort attending a national referral centre. The cohort was categorised into HTLV-1 symptomatic patients (SPs) (ATLL, HAM/TSP, Strongyloidiasis and HTLV associated inflammatory disease (HAID)) and HTLV-1 asymptomatic carriers (ACs). The cohort was reviewed for diagnosis of bronchiectasis. 34/246 ACs and 30/167 SPs had been investigated for respiratory symptoms by computer tomography (CT) with productive cough +/- recurrent chest infections the predominant indications. Bronchiectasis was diagnosed in one AC (1/246) and 13 SPs (2 HAID, 1 ATLL, 10 HAM/TSP) (13/167, RR 19.2 95 % CI 2.5-14.5, p = 0.004) with high resolution CT. In the multivariate analysis ethnicity (p = 0.02) and disease state (p < 0.001) were independent predictors for bronchiectasis. The relative risk of bronchiectasis in SPs was 19.2 (95 % CI 2.5-14.5, p = 0.004) and in HAM/TSP patients compared with all other categories 8.4 (95 % CI 2.7-26.1, p = 0.0002). Subjects not of African/Afro-Caribbean ethnicity had an increased prevalence of bronchiectasis (RR 3.45 95 % 1.2-9.7, p = 0.02). Bronchiectasis was common in the cohort (3.4 %). Risk factors were a prior diagnosis of HAM/TSP and ethnicity but not HTLV-1 viral load, age and gender. The spectrum of HTLV-associated disease should now include bronchiectasis and HTLV serology should be considered in patients with unexplained bronchiectasis.

25 September 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
PDF file
SHShohreh Honarbakhsh
Shohreh Honarbakhsh
RSRichard J. Schilling
Richard J. Schilling
RPRui Providencia
Rui Providencia
EKEmily Keating
Emily Keating
SSSimon Sporton
Simon Sporton
RHRoss J. Hunter
Ross J. Hunter
Introduction: Identifying drivers in persistent atrial fibrillation (AF) remains challenging. We sought to validate an automated system for detection of focal activation using basket and PentaRay catheters in AF.Methods: Patients having ablation for atrial tachycardia (AT) and persistent AF were mapped. Thirty‐second unipolar basket and PentaRay recordings were analyzed using CARTOFINDER. Focal activation or “region of interest” (ROI) was defined as more than or equal to 2 consecutive focal activations with one electrode leading relative to its neighbors with QS morphology on the unipolar electrogram. ROI was validated in AT. AF patients were mapped to (1) look for evidence of focal activations on wavefront maps, (2) evaluate whether these were detected as ROI on basket recordings, and (3) whether these sites could be identified on sequential PentaRay recordings.Results: ROIs were identified in five focal ATs but none of 16 reentrant ATs. Twenty‐eight AF patients had 35 focal drivers identified from basket wavefront maps with an ablation response in all (16 cycle length slowing and 19 AF termination). Thirty focal activations were detected on basket ROI maps (86%). Twenty‐three of 28 patients had sequential PentaRay mapping and 22 of 30 focal drivers in these patients (73%) were identified as ROI. These drivers had greater temporal stability (3.6 ± 0.6 vs 2.7 ± 0.6; P < 0.001), higher recurrence rate (12.4 ± 2.7 vs 7.2 ± 0.9; P < 0.001), and more frequently were associated with AF termination ( P < 0.001) compared with those not identified as ROI.Conclusions: Focal activations can be detected in AF using sequential recordings. The ablation response at focal sources suggests they may be viable therapeutic targets.

27 July 2022 in EP Europace
Verified
Journal Article
Closed access
PDF file
PWPeter H Waddingham
Peter H Waddingham
JEJames Elliott
James Elliott
ABAlexander Bates
Alexander Bates
JBJames Bilham
James Bilham
AMAmal Muthumala
Amal Muthumala
ACAnthony W C Chow
Anthony W C Chow
To determine the incidence, clinical features, management, and outcomes of pacemaker (PM) and implantable cardioverter-defibrillator (ICD) lead cardiac perforation. Cardiac perforations due to PM and ICD leads are rare but serious complications. Clinical features vary widely and may cause diagnostic delay. Management strategies are non-guideline based due to paucity of data. A multicentre retrospective series including 3 UK cardiac tertiary centres from 2016 to 2020. Patient, device, and lead characteristics were obtained including 6-month outcomes. Seventy cases of perforation were identified from 10 631 procedures; perforation rate was 0.50% for local implants. Thirty-nine (56%) patients were female, mean ( ± standard deviation) age 74 ( ± 13.8) years. Left ventricular ejection fraction 51 ( ± 13.2) %. Median time to diagnosis was 9 (range: 0–989) days. Computed tomography (CT) diagnosed perforation with 97% sensitivity. Lead parameter abnormalities were present in 86% (whole cohort) and 98.6% for perforations diagnosed >24 h. Chest pain was the commonest symptom, present in 46%. The management strategy was percutaneous in 98.6% with complete procedural success in 98.6%. Pericardial effusion with tamponade was present in 17% and was associated with significantly increased mortality and major complications. Anticoagulation status was associated with tamponade by multivariate analysis (odds ratio 21.7, 95% confidence interval: 1.7–275.5, P = 0.018). Perforation was rare (0.50%) and managed successfully by a percutaneous strategy with good outcomes. Tamponade was associated with increased mortality and major complications. Anticoagulation status was an independent predictor of tamponade. Case complexity is highly variable and requires skilled operators with a multi-disciplinary approach to achieve good outcomes.

1 March 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
MAMaclean
Maclean
KMKarishma Mahtani
Karishma Mahtani
SHShohreh Honarbakhsh
Shohreh Honarbakhsh
CBCharles Butcher
Charles Butcher
NANikhil Ahluwalia
Nikhil Ahluwalia
ACAnthony Chow
Anthony Chow
BACKGROUND: Antimicrobial envelopes reduce the incidence of cardiac implantable electronic device infections, but their cost restricts routine use in the United Kingdom. Risk scoring could help to identify which patients would most benefit from this technology. METHODS: A novel risk score (BLISTER [Blood results, Long procedure time, Immunosuppressed, Sixty years old (or younger), Type of procedure, Early re-intervention, Repeat procedure]) was derived from multivariate analysis of factors associated with cardiac implantable electronic device infection. Diagnostic utility was assessed against the existing PADIT score (Prior procedure, Age, Depressed renal function, Immunocompromised, Type of procedure) in both standard and high-risk external validation cohorts, and cost-utility models examined different BLISTER and PADIT score thresholds for TYRX (Medtronic; Minneapolis, MN) antimicrobial envelope allocation. RESULTS: In a derivation cohort (n=7383), cardiac implantable electronic device infection occurred in 59 individuals within 12 months of a procedure (event rate, 0.8%). In addition to the PADIT score constituents, lead extraction (hazard ratio, 3.3 [95% CI, 1.9–6.1]; P 50 mg/L (hazard ratio, 3.0 [95% CI, 1.4–6.4]; P =0.005), reintervention within 2 years (hazard ratio, 10.1 [95% CI, 5.6–17.9]; P <0.0001), and top-quartile procedure duration (hazard ratio, 2.6 [95% CI, 1.6–4.1]; P =0.001) were independent predictors of infection. The BLISTER score demonstrated superior discriminative performance versus PADIT in the standard risk (n=2854, event rate: 0.8%, area under the curve, 0.82 versus 0.71; P =0.001) and high-risk validation cohorts (n=1961, event rate: 2.0%, area under the curve, 0.77 versus 0.69; P =0.001), and in all patients (n=12 198, event rate: 1%, area under the curve, 0.8 versus 0.75, P =0.002). In decision-analytic modeling, the optimum scenario assigned antimicrobial envelopes to patients with BLISTER scores ≥6 (10.8%), delivering a significant reduction in infections (relative risk reduction, 30%; P =0.036) within the National Institute for Health and Care Excellence cost-utility thresholds (incremental cost-effectiveness ratio, £18 446). CONCLUSIONS: The BLISTER score ( https://qxmd.com/calculate/calculator_876/the-blister-score-for-cied-infection ) was a valid predictor of cardiac implantable electronic device infection, and could facilitate cost-effective antimicrobial envelope allocation to high-risk patients.